Skip to main content
SpringerLink
Log in

Nonsteroidal anti-inflammatory drugs and the induction of apoptosis in colon cells: Evidence for PHS-dependent and PHS-independent mechanisms

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

NSAIDs are potent chemopreventive agents for colon cancer. Although their mechanism of action is unknown, it probably relates to their modulation of colon epithelial cell kinetics, i.e. apoptosis and/or cell proliferation. NSAIDs are pleiotropic in their biochemical activities; their best known effect is inhibition of prostaglandin H synthase (PHS), the enzyme catalyzing the biosynthesis of prostaglandins. Current data appear to lead to two conflicting conclusions. One body of data indicates that PHS is important in induction of apoptosis and colon carcinogenesis and that its inhibition by NSAIDs is required for induction of apoptosis and their overall chemopreventive effect. Another set of data indicates that NSAIDs may induce apoptosis and prevent colon cancer without inhibiting the activity of PHS. Both sides of this argument are presented and discussed. This apparent contradiction may be resolved if one accepts that both mechanisms are correct but that they act on different steps of this multistep process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shiff SJ, Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions. Gastroenterology 1997; 113: 1992–1998.

    Google Scholar 

  2. Levy GN. Prostaglandin H synthases, nonsteroidal antiinflammatory drugs, and colon cancer. FASEB J 1997; 11: 234–247.

    Google Scholar 

  3. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575–5589.

    Google Scholar 

  4. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature—New Biology 1971; 231: 232–235.

    Google Scholar 

  5. Abramson SB, Weissmann G. The mechanisms of action of nonsteroidal anti-inflammatory drugs. Arthritis & Rheumatism 1989; 32: 1–9.

    Google Scholar 

  6. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96: 491–503.

    Google Scholar 

  7. Shiff SJ, Koutsos M.I, Qiao L, Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 222: 179–188.

    Google Scholar 

  8. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237–245.

    Google Scholar 

  9. Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 1994; 107: 3569–3577.

    Google Scholar 

  10. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer Cancer Res 1995; 55: 1811–1816.

    Google Scholar 

  11. Goldberg Y, Nassif II, Pittas A, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996; 12: 893–901.

    Google Scholar 

  12. Qiao L, Hanif R, Sphicas E, Shiff SJ, Rigas B. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem. Pharmacol 1998; 55: 53–64.

    Google Scholar 

  13. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide inhibits the proliferation of colon cancer cells—diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett 1997; 115: 229–234.

    Google Scholar 

  14. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide induces several subpopulations of colon cancer cells, defined by PCNA/Ki-67 and DNA strand breaks. Biochimica et Biophysica Acta—Molecular Cell Research. 1997; 1359: 222–232.

    Google Scholar 

  15. Elder DJE, Hague A, Hicks DJ, Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res 1996; 56: 2273–2276.

    Google Scholar 

  16. Piazza GA, Rahm ALK, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55: 3110–3116.

    Google Scholar 

  17. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413–421.

    Google Scholar 

  18. Elder DJE, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drug—independence from COX-2 protein expression. Clin Cancer Res 1997; 3: 1679–1683.

    Google Scholar 

  19. Tsujitani S, Shirai H, Tatebe S, et al. Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma. Cancer 1996; 77: 1711–1716.

    Google Scholar 

  20. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994–998.

    Google Scholar 

  21. Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362–366.

    Google Scholar 

  22. Winde G, Schmid KW, Brandt B, Muller O, Osswald H. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Diseases of the Colon & Rectum 1997; 40: 1156–1168.

    Google Scholar 

  23. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bünte H. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis Colon Rectum 1995; 38: 813–830.

    Google Scholar 

  24. Aoki T, Boland CR, Brenner DE. Aspirin modulation of premalignant biomarkers in rectal mucosa of high-risk subjects. Gastroenterology 1996; 110: A484.

    Google Scholar 

  25. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. Journal of Biological Chemistry 1996; 271: 33157–33160.

    Google Scholar 

  26. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816–4820.

    Google Scholar 

  27. Bennett A, Tacca MD, Stamford IF, Zebro T. Prostaglandins from tumours of human large bowel. Br J Cancer 1977; 35: 881–884.

    Google Scholar 

  28. Kubota Y, Sunouchi K, Ono M, Sawada T, Muto T. Local immunity and metastasis of colorectal carcinoma. Diseases of the Colon & Rectum 1992; 35: 645–650.

    Google Scholar 

  29. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518–523.

    Google Scholar 

  30. Nugent KP, Spigelman AD, Phillips RKS. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Diseases of the Colon & Rectum 1996; 39, 659–662.

    Google Scholar 

  31. Giardiello FM, Spannhake EW, DuBois RN, et al. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Digestive Diseases & Sciences 1998; 43: 311–316.

    Google Scholar 

  32. Yang VW, Shields JM, Hamilton SR, et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998; 58: 1750–1753.

    Google Scholar 

  33. Rao CV, Rivenson R, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464–1472.

    Google Scholar 

  34. Qiao L, Kozoni V, Tsioulias GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochimica Biophysica et Acta 1258: 215–223.

  35. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochimica Biophysica et Acta. 1996; 1300: 240–246.

    Google Scholar 

  36. Sheng HM, Shao JY, Morrow JD, Beauchamp RD, Dubois RN. Modulation of apoptosis and bcl-2 expression by prostaglandin E-2 in human colon cancer cells. Cancer Res 1998; 58: 362–366.

    Google Scholar 

  37. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and carcinomas. Gastroenterology 1994; 107: 1183–1188.

    Google Scholar 

  38. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and-2 protein in human colon cancer. Cancer Res 1995; 55: 2556–2559.

    Google Scholar 

  39. Tsujii M. and DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493–501.

    Google Scholar 

  40. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803–809.

    Google Scholar 

  41. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566–4569.

    Google Scholar 

  42. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254–2259.

    Google Scholar 

  43. Thompson HJ, Briggs S, Paranka NS, et al. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst 1995; 87: 1259–1260.

    Google Scholar 

  44. Alberts DS, Hixson L, Ahnen D, et al. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase. Journal of Cellular Biochemistry-supplement 1995; 22: 18–23.

    Google Scholar 

  45. de Mello MC, Bayer BM, Beaven MA. Evidence that prostaglandins do not have a role in the cytostatic action of anti-inflammatory drugs. Biochem. Pharmacol 1980; 29: 311–318.

    Google Scholar 

  46. McDougall CJ, Ngoi SS, Goldman IS, et al. Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res 1990; 50: 8023–8027.

    Google Scholar 

  47. Tsioulias G, Godwin TA, Goldstein MF, et al. Loss of colonic HLA antigens in familial adenomatous polyposis. Cancer Res 1992; 52: 3449–3452.

    Google Scholar 

  48. Tsioulias GJ, Triadafilopoulos G, Goldin E, et al. Expression of HLA class I antigens in sporadic adenomas and histologically normal mucosa of the colon. Cancer Res 1993; 53: 2374–2378.

    Google Scholar 

  49. Arvind P, Papavassiliou ED, Tsioulias GJ, Qiao L, Lovelace CIP, Rigas B. PGE2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. Biochemistry 1995; 34: 5604–5609.

    Google Scholar 

  50. Arvind P, Qiao L, Papavassiliou ED, Goldin E, Koutsos M, Rigas B. Aspirin and aspirin-like drugs induce the expression of HLA-DR in HT29 colon adenocarcinoma cells. Int J Oncol 1996; 8: 1207–1211.

    Google Scholar 

  51. Rigas B, Tsioulias GJ, Allan C, Wali RK, Brasitus TA. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology 1994; 83: 319–323.

    Google Scholar 

  52. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79: 1147–1156.

    Google Scholar 

  53. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 1998; 19: 49–53.

    Google Scholar 

  54. Saez E. Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPAR-gamma enhance colon polyp formation. Nature Med 1998; 4: 1058–1061.

    Google Scholar 

  55. Lefebvre, AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMIN/+ mice. Nature Med 1998; 4: 1053–1057.

    Google Scholar 

  56. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR-gamma. Nature Med 1998; 4: 1046–1052.

    Google Scholar 

  57. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. Journal of Biological Chemistry 1997; 272: 3406–3410.

    Google Scholar 

  58. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 1997; 94: 2869–2873.

    Google Scholar 

  59. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA 1998; 95: 681–686.

    Google Scholar 

  60. Takahashi M, Fukutake M, Yokota S, Ishida K, Wakabayashi K, Sugimura T. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. J Cancer Res Clin Oncol 1996; 122: 219–222.

    Google Scholar 

  61. Rigas B. and Shiff SJ. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Med Hypotheses 1999; in press.

Download references

Author information

Authors and Affiliations

  1. Rockefeller University, New York, NY, 10021

    B. Rigas & S. J. Shiff

Authors
  1. B. Rigas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. J. Shiff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rigas, B., Shiff, S.J. Nonsteroidal anti-inflammatory drugs and the induction of apoptosis in colon cells: Evidence for PHS-dependent and PHS-independent mechanisms. Apoptosis 4, 373–381 (1999). https://doi.org/10.1023/A:1009699321946

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009699321946

Search

Navigation